Last reviewed · How we verify
Nanocrystalline megestrol acetate
At a glance
| Generic name | Nanocrystalline megestrol acetate |
|---|---|
| Sponsor | Guangzhou Institute of Respiratory Disease |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Megestrol Acetate for First-Line Treatment of Malnourished Non-Small Cell Lung Cancer (PHASE3)
- Nano-Megestrol Acetate for Cancer Cachexia in Advanced Pancreatic Cancer (NA)
- Nanocrystalline Megestrol Acetate for Cachectic Stage Locally Advanced Hepatocellular Carcinoma (PHASE3)
- A Clinical Study of Nanocrystalline Megestrol Acetate in Concurrent Chemoradiotherapy for Locally Advanced Cervical Cancer (PHASE1)
- Nano-crystalline Megestrol Acetate for Chemotherapy-induced Nausea and Vomiting (PHASE2)
- A Prospective Real-World Observational Study of Nanocrystalline Megestrol Acetate in Patients With Cancer Cachexia (PHASE4)
- Nanocrystalline Megestrol Acetate in Concurrent Chemoradiotherapy for Locally Advanced Non-Small Cell Lung Cancer (PHASE3)
- Nanocrystalline Megestrol for Managing Chemotherapy-Induced Nausea and Vomiting (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: